Page last updated: 2024-10-17

choline and Recrudescence

choline has been researched along with Recrudescence in 77 studies

Research Excerpts

ExcerptRelevanceReference
"We aimed to prospectively investigate the relationships of circulating choline and betaine with cardiovascular events and recurrent stroke in patients with ischemic stroke."8.02Plasma choline and betaine and risks of cardiovascular events and recurrent stroke after ischemic stroke. ( Bu, X; Che, B; Du, J; He, J; Ju, Z; Miao, M; Peng, H; Wang, A; Xu, T; Zhang, J; Zhang, Y; Zhong, C, 2021)
"We report the incidental finding of a pituitary macroadenoma on an F-choline PET/CT in a patient with recurrent prostate cancer."7.83Pituitary Non-Functioning Adenoma Disclosed at 18F-Choline PET/CT to Investigate a Prostate Cancer Relapse. ( Colletti, PM; Maffione, AM; Mandoliti, G; Pasini, F; Rubello, D, 2016)
"For a biochemical recurrence of disease (prostate-specific antigen level, 0."5.51Pleural Mesothelioma Detects by 18F-Choline PET/CT in a Patient With Biochemical Recurrence of Prostate Cancer. ( Di Gregorio, F; Evangelista, L; Ferretti, G; Rensi, M, 2019)
"F-FDG PET showed no uptake of the residual tumor, whereas F-choline depicted highly metabolic residual disease uptake with excellent delineation of local recurrence."5.5118F-Choline PET/CT Imaging for Intracranial Hemangiopericytoma Recurrence. ( Cassou-Mounat, T; Huchet, V; Jehanno, N; Luporsi, M; Mammar, H, 2019)
"We aimed to prospectively investigate the relationships of circulating choline and betaine with cardiovascular events and recurrent stroke in patients with ischemic stroke."4.02Plasma choline and betaine and risks of cardiovascular events and recurrent stroke after ischemic stroke. ( Bu, X; Che, B; Du, J; He, J; Ju, Z; Miao, M; Peng, H; Wang, A; Xu, T; Zhang, J; Zhang, Y; Zhong, C, 2021)
"To compare the performance of the quantitative analysis of the hepatobiliary phase (HBP) tumor enhancement in gadobenate dimeglumine (Gd-BOPTA)-enhanced MRI and of dual-tracer 18F-FDG and 18F-fluorocholine (FCH) PET/CT for the prediction of tumor aggressiveness and recurrence-free survival (RFS) in resectable hepatocellular carcinoma (HCC)."3.96Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT. ( Amaddeo, G; Calderaro, J; Chalaye, J; Galletto Pregliasco, A; Itti, E; Kharrat, R; Kobeiter, H; Laurent, A; Legou, F; Luciani, A; Mulé, S; Regnault, H; Tacher, V; Tenenhaus, A, 2020)
"We report the incidental finding of a pituitary macroadenoma on an F-choline PET/CT in a patient with recurrent prostate cancer."3.83Pituitary Non-Functioning Adenoma Disclosed at 18F-Choline PET/CT to Investigate a Prostate Cancer Relapse. ( Colletti, PM; Maffione, AM; Mandoliti, G; Pasini, F; Rubello, D, 2016)
"The authors examined the levels of NAA, creatine plus phosphocreatine, and choline-containing molecules in the left dorsolateral prefrontal cortex of 14 bipolar disorder patients (mean age=15."3.73Reduced NAA levels in the dorsolateral prefrontal cortex of young bipolar patients. ( Axelson, D; Birmaher, B; Brambilla, P; Keshavan, MS; Nicoletti, MA; Ramos, RT; Ryan, N; Sassi, RB; Soares, JC; Stanley, JA, 2005)
"In the multiple sclerosis white matter lesions, N-acetylaspartate (NAA), choline (Cho), inositol (Ins), and creatine (Cr) peaks did not vary significantly over the entire period of the study in the untreated group."3.701H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study. ( Alberti, A; Gallai, V; Gobbi, G; Orlacchio, A; Pelliccioli, GP; Presciutti, O; Sarchielli, P; Tarducci, R, 1998)
"Prostate cancer is the second leading cause of cancer-related deaths in men in the United States."3.01PSMA PET imaging in the diagnosis and management of prostate cancer. ( Behr, S; Houshmand, S; Lawhn-Heath, C, 2023)
"This prospective study included 250 prostate cancer patients with PSA relapse who underwent (18)F-FCH PET/CT."2.78Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. ( Beheshti, M; Haim, S; Kunit, T; Langsteger, W; Loidl, W; Nader, M; Steinmair, M; Waldenberger, P; Zakavi, R, 2013)
"Findings consistent with recurrent prostate cancer were noted on FCH PET/CT in 31/50 (62%) patients, with positive findings in 17/18 (94%), and 11/13 (85%), 2/7 (29%), and 1/12 (8%) patients with PSA >4, >2-4, >0."2.77Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging. ( Coel, MN; Kwee, SA; Lim, J, 2012)
"In patients with advanced head and neck cancer who have received combined therapy, a second post-treatment PET/CT examination to check for late recurrences should be performed within 4-6 months after the first post-treatment PET/CT examination."2.7518F-FDG versus 11C-choline PET/CT for the imaging of advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy: the time period during which PET/CT can reliably detect non-recurrence. ( Ito, K; Kubota, K; Matsuda, H; Morooka, M; Shiibashi, M; Yokoyama, J, 2010)
"Twenty patients had depression recurrence, and 23 patients reached AD discontinuation."1.62Choline elevation in amygdala region at recovery indicates longer survival without depressive episode: a magnetic resonance spectroscopy study. ( Bajs Janović, M; Erdeljić Turk, V; Foro, T; Henigsberg, N; Hrabač, P; Kalember, P; Ozretić, D; Radoš, M; Šarac, H; Savić, A; Šečić, A, 2021)
"Patients with prostate cancer are monitored by prostate-specific antigen (PSA) evaluation and PET [PET/computed tomography (CT)]."1.5118F-choline positron emission tomography/computed tomography for the detection of prostate cancer relapse: assessment of maximum standardized uptake value correlation with prostate-specific antigen levels. ( Cholewiński, W; Czepczyński, R; Miechowicz, I; Ruchała, M; Siminiak, N; Wojciechowska, K, 2019)
"For a biochemical recurrence of disease (prostate-specific antigen level, 0."1.51Pleural Mesothelioma Detects by 18F-Choline PET/CT in a Patient With Biochemical Recurrence of Prostate Cancer. ( Di Gregorio, F; Evangelista, L; Ferretti, G; Rensi, M, 2019)
"F-FDG PET showed no uptake of the residual tumor, whereas F-choline depicted highly metabolic residual disease uptake with excellent delineation of local recurrence."1.5118F-Choline PET/CT Imaging for Intracranial Hemangiopericytoma Recurrence. ( Cassou-Mounat, T; Huchet, V; Jehanno, N; Luporsi, M; Mammar, H, 2019)
"In patients with early recurrence of PC, F-FCH PET/CT is able to detect OMD in 40% of cases."1.48Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml. ( Agostini, A; Basso, U; Cuppari, L; Evangelista, L; Gardi, M; Guttilla, A; Ruggera, L; Saladini, G, 2018)
"Patients with suspected recurrence of prostate cancer undergoing [18F]fluoromethyl choline ([18F]FCH) PET/CT were retrospectively evaluated to investigate the influence of hormonal therapy (HT) in [18F]FCH uptake."1.43Influence of hormonal therapy in prostate cancer patients undergoing [18F]fluoromethyl choline PET/CT: a retrospective study. ( Aristei, C; Bellavita, R; Buresta, T; Ferretti, F; Fravolini, ML; Mearini, L; Palumbo, B; Palumbo, I; Pelliccia, G; Radicchia, V; Scialpi, M; Sivolella, S, 2016)
"multi-parametric MRI in the prostate cancer relapse."1.42(11)C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer. ( Cozar, M; Escobar, M; Garcia, JR; Moragas, M; Romera, N; Soler, M, 2015)
"Early F-choline images improve pelvic prostate cancer lesion clarity."1.42Optimized protocol for (18)F-choline PET/CT in patients with biochemically relapsed prostate cancer: experiences on 250 consecutive cases. ( Chondrogiannis, S; Colletti, PM; Grassetto, G; Marzola, MC; Massaro, A; Rampin, L; Rubello, D, 2015)
"The reviewers assessed for local recurrence in the prostatectomy bed as well as LN and bone metastases, rating their diagnostic confidence with a 5-point scoring system for each location."1.40Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil. ( Froemming, AT; Hagen, CE; Kawashima, A; Kitajima, K; Murphy, RC; Nathan, MA; Takahashi, N, 2014)
"In the present case, atypical cancer recurrence in the right distal lower leg was suspected on 18F-FEC PET/CT in a patient with a history of prostate cancer and an increased prostate-specific antigen level."1.40Unexpected diagnosis of peripheral schwannoma on 18F-fluoroethylcholine PET/CT for localization of prostate cancer recurrence and biopsy under real-time PET/ultrasound fusion guidance. ( Drescher, R; Freesmeyer, M; Winkens, T, 2014)
"Fifty-five patients with biopsy-proven prostate cancer or suspected recurrent prostate cancer were examined with simultaneous [18F] choline Positron emission tomography (PET)/MRI at 3 T."1.40Quantitative evaluation of bone metastases from prostate cancer with simultaneous [18F] choline PET/MRI: combined SUV and ADC analysis. ( Heusch, P; Lauenstein, TC; Lipponer, C; Nagarajah, J; Nensa, F; Pöppel, TD; Rübben, H; Schlosser, TW; Wetter, A, 2014)
"To evaluate, in prostate cancer (PCa) patients the potential of (11)C-choline PET/CT as a guide to helical tomotherapy (HTT) of lymph-node (LN) relapses with simultaneous integrated boost (SIB)."1.40(11)C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients. ( Berardi, G; Busnardo, E; Crivellaro, C; Di Muzio, N; Fiorino, C; Fodor, A; Gianolli, L; Giovacchini, G; Incerti, E; Kirienko, M; Messa, C; Picchio, M, 2014)
"Disease relapse was local in 17% of cases, distant in 66%, and combined in 17%."1.39Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution. ( Al-Nahhas, A; Castellucci, P; Chondrogiannis, S; Colletti, PM; Ferretti, A; Grassetto, G; Marcolongo, A; Marzola, MC; Massaro, A; Picchio, M; Rampin, L; Rubello, D, 2013)
"The early detection of the site of recurrence could lead to a prompt instauration of the most appropriate treatment, i."1.37Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? ( Allegri, V; Ambrosini, V; Boschi, S; Castellucci, P; Fanti, S; Fuccio, C; Martorana, G; Marzola, MC; Montini, GC; Nanni, C; Rubello, D; Santi, I; Schiavina, R, 2011)
"Recurrences were eventually confirmed in eight patients after the posttreatment PET/CT examination."1.36Comparison of 18F-FDG and 11C-choline PET/CT for detecting recurrences in patients with nonsquamous cell head and neck malignancies. ( Ito, K; Kubota, K; Morooka, M; Yokoyama, J, 2010)
"The neural underpinnings of major depressive disorder (MDD) are unknown but there is evidence for structural alteration in the hippocampus that may become more pronounced over the course of illness."1.35Hippocampal metabolic abnormalities at first onset and with recurrent episodes of a major depressive disorder: a proton magnetic resonance spectroscopy study. ( Hall, GB; MacQueen, GM; Milne, A; Soreni, N; Yucel, K, 2009)
"One hundred consecutive prostate cancer patients with a persistent increase in serum PSA (>0."1.33[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. ( Baresic, T; Borsatti, E; Bortolus, R; Canzonieri, V; Cimitan, M; Drigo, A; Garbeglio, A; Morassut, S; Trovò, MG, 2006)
"In pretreated glioblastoma metabolic data of MRSI seem to be potentially helpful to differentiate tumorous and non tumorous enhancement phenomena after local immunotherapy, which might be useful for further treatment decisions."1.31Comparative follow-up of enhancement phenomena with MRI and Proton MR Spectroscopic Imaging after intralesional immunotherapy in glioblastoma--Report of two exceptional cases. ( Engelbrecht, V; Floeth, FW; Weber, F; Wittsack, HJ, 2002)

Research

Studies (77)

TimeframeStudies, this research(%)All Research%
pre-19901 (1.30)18.7374
1990's5 (6.49)18.2507
2000's9 (11.69)29.6817
2010's54 (70.13)24.3611
2020's8 (10.39)2.80

Authors

AuthorsStudies
Langé, M1
Magné, N1
Zhou, K1
Bellanger, M1
Latorzeff, I1
Pommier, P1
Martin, E2
Paumier, A1
Béra, G1
Supiot, S1
Houshmand, S1
Lawhn-Heath, C1
Behr, S1
Henigsberg, N2
Savić, A2
Radoš, M4
Šarac, H2
Šečić, A2
Bajs Janović, M2
Foro, T1
Ozretić, D2
Erdeljić Turk, V2
Hrabač, P2
Kalember, P2
Siminiak, N1
Wojciechowska, K1
Miechowicz, I1
Cholewiński, W1
Ruchała, M1
Czepczyński, R1
Witkowska-Patena, E1
Giżewska, A1
Dziuk, M1
Miśko, J1
Budzyńska, A1
Walęcka-Mazur, A1
Nguyen, BD1
Heller, MT1
Roarke, MC1
Mulé, S1
Chalaye, J1
Legou, F1
Tenenhaus, A1
Calderaro, J1
Galletto Pregliasco, A1
Laurent, A1
Kharrat, R1
Amaddeo, G1
Regnault, H1
Tacher, V1
Kobeiter, H1
Itti, E1
Luciani, A1
Evangelista, L5
Ravelli, I1
Magnani, F1
Iacobone, M1
Giraudo, C1
Camozzi, V1
Spimpolo, A1
Cecchin, D1
Telo, S1
Fanti, S8
Nanni, C4
Lambertini, A1
Picchio, M4
Gianolli, L2
Schiavina, R6
Bianchi, L1
Briganti, A1
Mapelli, P1
Castellucci, P9
Farolfi, A1
Zhong, C1
Miao, M1
Che, B1
Du, J1
Wang, A1
Peng, H1
Bu, X1
Zhang, J1
Ju, Z1
Xu, T1
He, J1
Zhang, Y1
Haroon, A1
Syed, R1
Endozo, R1
Allie, R1
Freeman, A1
Emberton, M1
Bomanji, J1
Hatzl, M1
Röper-Kelmayr, JC1
Fellner, FA1
Gabriel, M1
Vadi, SK1
Singh, B1
Basher, RK1
Watts, A1
Sood, AK1
Lal, A1
Kakkar, N1
Singh, SK1
Parekh, A1
Hagan, I1
Capaldi, L1
Lyburn, I1
Cuppari, L1
Guttilla, A3
Gardi, M1
Agostini, A1
Ruggera, L1
Basso, U1
Saladini, G2
Lépinoy, A1
Silva, YE1
Bertaut, A1
Quivrin, M1
Aubignac, L1
Cochet, A1
Créhange, G1
Rensi, M1
Ferretti, G1
Di Gregorio, F1
Gómez-de la Fuente, FJ1
Martínez-Rodríguez, I1
De Arcocha-Torres, M1
Quirce, R1
Jiménez-Bonilla, J1
Martínez-Amador, N1
Sánchez-Salmón, A1
Lucas-Velázquez, B1
Cuenca-Vera, O1
Banzo, I1
Jehanno, N1
Cassou-Mounat, T2
Mammar, H1
Luporsi, M1
Huchet, V2
Zattoni, F3
Colletti, PM5
Rubello, D10
Beheshti, M1
Haim, S1
Zakavi, R1
Steinmair, M1
Waldenberger, P1
Kunit, T1
Nader, M1
Langsteger, W1
Loidl, W1
Brogsitter, C1
Zöphel, K1
Kotzerke, J1
Kitajima, K2
Murphy, RC2
Nathan, MA2
Chondrogiannis, S4
Marzola, MC7
Ferretti, A2
Maffione, AM3
Rampin, L4
Grassetto, G4
Afshar-Oromieh, A1
Zechmann, CM1
Malcher, A1
Eder, M1
Eisenhut, M1
Linhart, HG1
Holland-Letz, T1
Hadaschik, BA1
Giesel, FL1
Debus, J1
Haberkorn, U1
Wetter, A2
Lipponer, C2
Nensa, F2
Heusch, P2
Rübben, H2
Altenbernd, JC1
Schlosser, T1
Bockisch, A1
Pöppel, T1
Lauenstein, T1
Nagarajah, J2
Ceci, F2
Graziani, T1
Brunocilla, E2
Mazzarotto, R1
Ntreta, M1
Lodi, F2
Martorana, G5
Froemming, AT1
Hagen, CE1
Takahashi, N1
Kawashima, A1
Freesmeyer, M1
Drescher, R1
Winkens, T1
Schlosser, TW1
Pöppel, TD1
Lauenstein, TC1
Berardi, G1
Fodor, A1
Busnardo, E1
Crivellaro, C1
Giovacchini, G1
Fiorino, C1
Kirienko, M1
Incerti, E1
Messa, C1
Di Muzio, N1
Palumbo, B1
Sivolella, S1
Palumbo, I1
Buresta, T1
Radicchia, V1
Fravolini, ML1
Ferretti, F1
Bellavita, R1
Mearini, L1
Scialpi, M1
Aristei, C1
Pelliccia, G1
Veronese, E1
Massaro, A3
Bolcaen, J1
Descamps, B1
Deblaere, K1
Boterberg, T1
De Vos Pharm, F1
Kalala, JP1
Van den Broecke, C1
Decrock, E1
Leybaert, L1
Vanhove, C1
Goethals, I1
Garcia, JR2
Cuberas, G1
Riera, E1
Soler, M2
Moragas, M2
Lomeña, F1
Romera, N1
Cozar, M1
Escobar, M1
Colombié, M1
Campion, L1
Bailly, C1
Rusu, D1
Rousseau, T1
Mathieu, C1
Ferrer, L1
Rousseau, N1
Kraeber-Bodéré, F1
Rousseau, C1
Minozzi, S1
Balduzzi, S1
Herrmann, K2
Krause, BJ2
Oyen, W1
Chiti, A1
Zanoni, L1
Pultrone, C1
Malizia, C2
Ferrari, M1
Rigatti, P1
Fonti, C1
Pfister, D1
Porres, D1
Heidenreich, A1
Heidegger, I1
Knuechel, R1
Steib, F1
Behrendt, FF1
Verburg, FA1
Zahr, NM1
Carr, RA1
Rohlfing, T1
Mayer, D1
Sullivan, EV1
Colrain, IM1
Pfefferbaum, A1
Balogova, S1
Nataf, V1
Calzada, M1
Kerrou, K1
Devaux, JY1
Mohty, M1
Talbot, JN1
Garderet, L1
von Eyben, FE1
Kairemo, K1
Mandoliti, G1
Pasini, F1
Steiner, Ch1
Vees, H1
Zaidi, H1
Wissmeyer, M1
Berrebi, O1
Kossovsky, MP1
Khan, HG1
Miralbell, R2
Ratib, O1
Buchegger, F1
Milne, A1
MacQueen, GM1
Yucel, K1
Soreni, N1
Hall, GB1
Jadvar, H1
Ito, K2
Yokoyama, J2
Kubota, K2
Morooka, M2
Shiibashi, M1
Matsuda, H1
Fuccio, C4
Santi, I1
Allegri, V1
Montini, GC1
Ambrosini, V2
Boschi, S2
Wu, HB1
Wang, QS1
Wang, MF1
Li, HS1
Al-Nahhas, A2
Würschmidt, F1
Petersen, C1
Wahl, A1
Dahle, J1
Kretschmer, M1
Celli, M1
Profitos, MB1
Pettinato, V1
Graute, V1
Jansen, N1
Ubleis, C1
Seitz, M1
Hartenbach, M1
Scherr, MK1
Thieme, S1
Cumming, P1
Klanke, K1
Tiling, R1
Bartenstein, P1
Hacker, M1
Soyka, JD1
Muster, MA1
Schmid, DT1
Seifert, B1
Schick, U1
Jorcano, S1
Zaugg, K1
Seifert, HH1
Veit-Haibach, P1
Strobel, K1
Schaefer, NG1
Husarik, DB1
Hany, TF1
Kwee, SA1
Coel, MN1
Lim, J1
Gu, CN1
Hunt, CH1
Lehman, VT1
Johnson, GB1
Diehn, FE1
Schwartz, KM1
Eckel, LJ1
Mamede, M1
Marcolongo, A1
Inglese, M1
Li, BS1
Rusinek, H1
Babb, JS1
Grossman, RI1
Gonen, O1
Obergriesser, T1
Ende, G1
Braus, DF1
Henn, FA1
Sassi, RB1
Stanley, JA1
Axelson, D1
Brambilla, P1
Nicoletti, MA1
Keshavan, MS1
Ramos, RT1
Ryan, N1
Birmaher, B1
Soares, JC1
Cimitan, M1
Bortolus, R1
Morassut, S1
Canzonieri, V1
Garbeglio, A1
Baresic, T1
Borsatti, E1
Drigo, A1
Trovò, MG1
Souvatzoglou, M1
Tuncel, M1
Buck, AK1
Praus, C1
Schuster, T1
Geinitz, H1
Treiber, U1
Schwaiger, M1
Bizzi, A1
Movsas, B1
Tedeschi, G1
Phillips, CL1
Okunieff, P1
Alger, JR1
Di Chiro, G1
Tsimmerman, IaS2
Kiseleva, RP1
Freĭnd, GG1
Pan, JW1
Hetherington, HP1
Vaughan, JT1
Mitchell, G1
Pohost, GM1
Whitaker, JN1
Sarchielli, P1
Presciutti, O1
Tarducci, R1
Gobbi, G1
Alberti, A1
Pelliccioli, GP1
Orlacchio, A1
Gallai, V1
Rabinovich, IM1
Banchenko, GV1
Rabinovich, OF1
Klijn, CJ1
Kappelle, LJ1
van der Grond, J1
Algra, A1
Tulleken, CA1
van Gijn, J1
Floeth, FW1
Wittsack, HJ1
Engelbrecht, V1
Weber, F1
Syman, LN1
Golovanova, ES1

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Inner Mongolia Stroke Project A Randomized Controlled Trial of Immediate Blood Pressure Reduction on Death and Major Disability in Patients With Acute Ischemic Stroke in China[NCT01840072]4,071 participants (Actual)Interventional2009-08-31Completed
Phase III Multicentre Prospective Comparative Study of Detection Rate of 18F-JK-PSMA-7 and of 18F-fluorocholine in Patients With Biochemical Recurrence of Prostate Cancer After Previous Treatment With Curative Intent[NCT05622162]Phase 3106 participants (Anticipated)Interventional2022-11-30Not yet recruiting
[NCT02964351]120 participants (Anticipated)Observational2016-12-31Not yet recruiting
Determination of the Diagnostic Detection Rate of Axumin (Fluciclovine) PET/CT Utilizing the High Resolution Digital Philips Vereos Scanner, in Patients With Biochemical Recurrence After Radical Prostatectomy[NCT04234399]22 participants (Actual)Observational2020-03-01Active, not recruiting
A Multi-center, Open-label, Single Arm Phase III Clinical Trial for the Diagnostic Efficacy Assessment and Safety Evaluation by [18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer[NCT05936658]Phase 389 participants (Anticipated)Interventional2023-05-08Recruiting
F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer Treated by Abiraterone Acetate or Enzalutamide[NCT01981707]Phase 2/Phase 312 participants (Actual)Interventional2013-12-31Terminated (stopped due to enrollment default)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

A Combination of All-cause Mortality and Major Disability at the 3-month Post-treatment Follow-up.

Major disability was defined as a score of 3 to 5 on the modified Rankin Scale at 3 months after randomization. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death (NCT01840072)
Timeframe: 3 months

InterventionParticipants (Count of Participants)
Usual Care502
Active Antihypertensive Treatment500

A Combination of Death Within 14 Days After Randomization and Major Disability at 14 Days or at Hospital Discharge if Earlier Than 14 Days.

Major disability was defined as a score of 3 to 5 on the modified Rankin Scale at 14 days after randomization. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death. (NCT01840072)
Timeframe: 2 weeks

Interventionparticipants (Number)
Usual Care681
Active Antihypertensive Treatment683

Cognitive Function (Montreal Cognitive Assessment)

Cognitive function was measured by Montreal Cognitive Assessment at 3 months after randomization. The MoCA is a 30-item test that evaluates the following seven cognitive domains: visuospatial/executive functions, naming, memory, attention, language, abstraction, and orientation. One point is added for participants with education <12 years. Scores on the MoCA range from 0 to 30 and cognitive impairment was defined as a score of <26. (NCT01840072)
Timeframe: Three months

InterventionMoCA score (Median)
Usual Care22
Active Antihypertensive Treatment22

Cognitive Function (the Mini-Mental State Examination)

Cognitive function was measured by the Mini-Mental State Examination at 3 months after randomization. The MMSE contains 20 items that test cognitive performance in domains including orientation, registration, attention and calculation, recall, language, and visual construction. MMSE scores were divided into three ordinal categories: 24-30 (no cognitive impairment), 19-23 (mild cognitive impairment), and 0-17 (severe cognitive impairment). (NCT01840072)
Timeframe: Three months

InterventionMMSE score (Median)
Usual Care26
Active Antihypertensive Treatment26

Long-term Neurological and Functional Status

Those patients who were still alive at hospital discharge were contacted by telephone to set up a follow-up clinical visit. Neurological function was assessed by the modified Rankin scale at the 3-month post-treatment follow-up visit. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death. Major disability was defined as a score of 3 to 5 on the modified Rankin Scale. (NCT01840072)
Timeframe: Three months

InterventionScore on modified Rankin scale (Median)
Usual Care1.0
Active Antihypertensive Treatment1.0

Mortality

Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information on clinical deaths will be obtained. (NCT01840072)
Timeframe: 3 months

Interventionparticipants (Number)
Active Antihypertensive Treatment68
Usual Care54

Other Vascular Events

Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information of vascular events, such as myocardial infarction, will be collected. (NCT01840072)
Timeframe: 3 months

Interventionparticipants (Number)
Usual Care59
Active Antihypertensive Treatment48

Recurrent Stroke

Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information of recurrent stroke will be collected. (NCT01840072)
Timeframe: 3 months

Interventionparticipants (Number)
Active Antihypertensive Treatment28
Usual Care43

Reviews

10 reviews available for choline and Recrudescence

ArticleYear
PSMA PET imaging in the diagnosis and management of prostate cancer.
    Abdominal radiology (New York), 2023, Volume: 48, Issue:12

    Topics: Choline; Humans; Male; Molecular Targeted Therapy; Neoplasm Staging; Positron Emission Tomography Co

2023
    Annals of nuclear medicine, 2020, Volume: 34, Issue:9

    Topics: Choline; Humans; Hyperparathyroidism; Magnetic Resonance Imaging; Positron Emission Tomography Compu

2020
Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis.
    Clinical nuclear medicine, 2013, Volume: 38, Issue:5

    Topics: Aged; Aged, 80 and over; Androgens; Choline; Humans; Male; Middle Aged; Multimodal Imaging; Positron

2013
18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients.
    European journal of nuclear medicine and molecular imaging, 2013, Volume: 40 Suppl 1

    Topics: Acetates; Carbon; Choline; Humans; Male; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tom

2013
11C-choline PET/CT and PSA kinetics.
    European journal of nuclear medicine and molecular imaging, 2013, Volume: 40 Suppl 1

    Topics: Carbon Radioisotopes; Choline; Humans; Male; Multimodal Imaging; Positron-Emission Tomography; Prost

2013
Choline PET/CT for imaging prostate cancer: an update.
    Annals of nuclear medicine, 2013, Volume: 27, Issue:7

    Topics: Choline; Humans; Male; Multimodal Imaging; Positron-Emission Tomography; Prostatic Neoplasms; Recurr

2013
New acquisition protocol of 18F-choline PET/CT in prostate cancer patients: review of the literature about methodology and proposal of standardization.
    BioMed research international, 2014, Volume: 2014

    Topics: Adult; Aged; Aged, 80 and over; Choline; Humans; Lymph Nodes; Male; Middle Aged; Positron-Emission T

2014
PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data.
    European journal of nuclear medicine and molecular imaging, 2016, Volume: 43, Issue:1

    Topics: Carbon Radioisotopes; Choline; Humans; Male; Positron-Emission Tomography; Prostatic Neoplasms; Recu

2016
Acquisition with (11)C-choline and (18)F-fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis.
    Annals of nuclear medicine, 2016, Volume: 30, Issue:6

    Topics: Carbon Radioisotopes; Choline; Fluorine Radioisotopes; Humans; Image Processing, Computer-Assisted;

2016
Prostate-specific antigen kinetics and choline PET/CT in patients with biochemical relapse after primary treatment for prostate cancer.
    Nuclear medicine communications, 2011, Volume: 32, Issue:6

    Topics: Choline; Humans; Kinetics; Male; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic

2011

Trials

10 trials available for choline and Recrudescence

ArticleYear
Head-to-Head Comparison of 18F-Prostate-Specific Membrane Antigen-1007 and 18F-Fluorocholine PET/CT in Biochemically Relapsed Prostate Cancer.
    Clinical nuclear medicine, 2019, Volume: 44, Issue:12

    Topics: Aged; Aged, 80 and over; Choline; Humans; Male; Middle Aged; Niacinamide; Oligopeptides; Positron Em

2019
Spectrum of metastatic and nonmetastatic skeletal findings with dual-phase 18F-FECH PET/CT in patients with biochemical relapse of prostate cancer.
    Nuclear medicine communications, 2017, Volume: 38, Issue:5

    Topics: Aged; Aged, 80 and over; Bone Neoplasms; Choline; Humans; Male; Middle Aged; Positron Emission Tomog

2017
Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013, Volume: 54, Issue:6

    Topics: Aged; Androgens; Choline; Humans; Kinetics; Male; Multimodal Imaging; Neoplasm Staging; Positron-Emi

2013
Dual-phase 11C-choline PET/computed tomography in the early evaluation of prostate cancer recurrence.
    Nuclear medicine communications, 2015, Volume: 36, Issue:1

    Topics: Aged; Carbon Radioisotopes; Choline; Feasibility Studies; Half-Life; Humans; Male; Multimodal Imagin

2015
(18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
    European journal of nuclear medicine and molecular imaging, 2016, Volume: 43, Issue:9

    Topics: Aged; Aged, 80 and over; Bone Neoplasms; Carbon Radioisotopes; Carboxylic Acids; Choline; Cyclobutan

2016
(18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
    European journal of nuclear medicine and molecular imaging, 2016, Volume: 43, Issue:9

    Topics: Aged; Aged, 80 and over; Bone Neoplasms; Carbon Radioisotopes; Carboxylic Acids; Choline; Cyclobutan

2016
(18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
    European journal of nuclear medicine and molecular imaging, 2016, Volume: 43, Issue:9

    Topics: Aged; Aged, 80 and over; Bone Neoplasms; Carbon Radioisotopes; Carboxylic Acids; Choline; Cyclobutan

2016
(18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
    European journal of nuclear medicine and molecular imaging, 2016, Volume: 43, Issue:9

    Topics: Aged; Aged, 80 and over; Bone Neoplasms; Carbon Radioisotopes; Carboxylic Acids; Choline; Cyclobutan

2016
18F-FDG versus 11C-choline PET/CT for the imaging of advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy: the time period during which PET/CT can reliably detect non-recurrence.
    European journal of nuclear medicine and molecular imaging, 2010, Volume: 37, Issue:7

    Topics: Aged; Carbon Radioisotopes; Choline; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Foll

2010
[18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes.
    Radiation oncology (London, England), 2011, May-01, Volume: 6

    Topics: Aged; Carcinoma; Choline; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Sta

2011
Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging.
    Annals of nuclear medicine, 2012, Volume: 26, Issue:6

    Topics: Aged; Aged, 80 and over; Choline; Disease Progression; Humans; Male; Middle Aged; Multimodal Imaging

2012
Diffusely elevated cerebral choline and creatine in relapsing-remitting multiple sclerosis.
    Magnetic resonance in medicine, 2003, Volume: 50, Issue:1

    Topics: Adult; Aspartic Acid; Brain; Choline; Corpus Callosum; Creatine; Diffusion; Female; Humans; Magnetic

2003
[A clinical study of Solcoseryl Dental Adhesive Paste and Mundisal gel in the treatment of chronic recurrent aphthous and herpetic stomatitides].
    Stomatologiia, 1999, Volume: 78, Issue:6

    Topics: Actihaemyl; Adult; Anti-Inflammatory Agents, Non-Steroidal; Choline; Chronic Disease; Drug Combinati

1999

Other Studies

57 other studies available for choline and Recrudescence

ArticleYear
[Intermediate-risk prostate cancer treated with exclusive external irradiation: Focus on anatomical sites of recurrence in two French trials].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2022, Volume: 26, Issue:5

    Topics: Choline; Humans; Male; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography;

2022
Choline elevation in amygdala region at recovery indicates longer survival without depressive episode: a magnetic resonance spectroscopy study.
    Psychopharmacology, 2021, Volume: 238, Issue:5

    Topics: Adult; Amygdala; Antidepressive Agents; Aspartic Acid; Brain; Choline; Depression; Humans; Magnetic

2021
18F-choline positron emission tomography/computed tomography for the detection of prostate cancer relapse: assessment of maximum standardized uptake value correlation with prostate-specific antigen levels.
    Nuclear medicine communications, 2019, Volume: 40, Issue:12

    Topics: Aged; Biological Transport; Choline; Humans; Male; Positron Emission Tomography Computed Tomography;

2019
Nodular Fat-Sparing Hepatic Parenchyma as 11C-Choline-Avid Finding on PET/CT.
    Clinical nuclear medicine, 2020, Volume: 45, Issue:3

    Topics: Adipose Tissue; Aged; Carbon Radioisotopes; Choline; Diagnosis, Differential; Humans; Liver; Male; M

2020
Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT.
    European radiology, 2020, Volume: 30, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Choline; Contrast Media; Disease-Free Sur

2020
Negative 11C-choline PET/computed tomography imaging in restaging of patients with prostate cancer with serum prostate-specific antigen values >20 ng/mL.
    Nuclear medicine communications, 2020, Volume: 41, Issue:11

    Topics: Aged; Carbon Radioisotopes; Choline; False Negative Reactions; Humans; Male; Middle Aged; Neoplasm S

2020
Plasma choline and betaine and risks of cardiovascular events and recurrent stroke after ischemic stroke.
    The American journal of clinical nutrition, 2021, 10-04, Volume: 114, Issue:4

    Topics: Aged; Betaine; Cardiovascular Diseases; Case-Control Studies; Choline; Female; Humans; Lipotropic Ag

2021
18F-Fluorocholine, 18F-FDG, and 18F-Fluoroethyl Tyrosine PET/CT in Parathyroid Cancer.
    Clinical nuclear medicine, 2017, Volume: 42, Issue:6

    Topics: Aged; Choline; Female; Fluorodeoxyglucose F18; Humans; Parathyroid Neoplasms; Positron Emission Tomo

2017
18F-Fluorocholine PET/CT Complementing the Role of Dynamic Contrast-Enhanced MRI for Providing Comprehensive Diagnostic Workup in Prostate Cancer Patients With Suspected Relapse Following Radical Prostatectomy.
    Clinical nuclear medicine, 2017, Volume: 42, Issue:8

    Topics: Aged; Choline; Contrast Media; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Stagi

2017
Incidental Papillary Bladder Carcinoma on 18F-Fluoromethylcholine PET/CT Undertaken to Evaluate Prostate Malignancy.
    Clinical nuclear medicine, 2017, Volume: 42, Issue:9

    Topics: Aged; Carcinoma, Papillary; Choline; Humans; Incidental Findings; Male; Positron Emission Tomography

2017
Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
    Nuclear medicine communications, 2018, Volume: 39, Issue:3

    Topics: Aged; Androgens; Choline; Humans; Male; Neoplasm Metastasis; Positron Emission Tomography Computed T

2018
Salvage extended field or involved field nodal irradiation in
    European journal of nuclear medicine and molecular imaging, 2019, Volume: 46, Issue:1

    Topics: Aged; Aged, 80 and over; Choline; Humans; Male; Middle Aged; Positron Emission Tomography Computed T

2019
Choline and N-acetyl aspartate levels in the dorsolateral prefrontal cortex at the beginning of the recovery phase as markers of increased risk for depressive episode recurrence under different duration of maintenance therapy and after it: a retrospective
    Croatian medical journal, 2018, Oct-31, Volume: 59, Issue:5

    Topics: Adolescent; Adult; Antidepressive Agents; Aspartic Acid; Biomarkers; Choline; Depressive Disorder; F

2018
Pleural Mesothelioma Detects by 18F-Choline PET/CT in a Patient With Biochemical Recurrence of Prostate Cancer.
    Clinical nuclear medicine, 2019, Volume: 44, Issue:2

    Topics: Aged; Choline; Humans; Male; Mesothelioma; Pleural Neoplasms; Positron Emission Tomography Computed

2019
Effect of positive carbon-11-choline PET/CT results in the therapeutic management of prostate cancer biochemical relapse.
    Nuclear medicine communications, 2019, Volume: 40, Issue:1

    Topics: Aged; Aged, 80 and over; Carbon Radioisotopes; Choline; Humans; Male; Middle Aged; Positron Emission

2019
18F-Choline PET/CT Imaging for Intracranial Hemangiopericytoma Recurrence.
    Clinical nuclear medicine, 2019, Volume: 44, Issue:4

    Topics: Brain Neoplasms; Choline; Hemangiopericytoma; Humans; Male; Middle Aged; Neoplasm, Residual; Positro

2019
Role of ¹⁸F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer.
    European journal of nuclear medicine and molecular imaging, 2013, Volume: 40, Issue:9

    Topics: Aged; Aged, 80 and over; Brachytherapy; Choline; Humans; Male; Middle Aged; Multimodal Imaging; Posi

2013
Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.
    European journal of nuclear medicine and molecular imaging, 2014, Volume: 41, Issue:1

    Topics: Aged; Aged, 80 and over; Antigens, Surface; Choline; Gallium Radioisotopes; Glutamate Carboxypeptida

2014
Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.
    European journal of nuclear medicine and molecular imaging, 2014, Volume: 41, Issue:1

    Topics: Aged; Aged, 80 and over; Antigens, Surface; Choline; Gallium Radioisotopes; Glutamate Carboxypeptida

2014
Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.
    European journal of nuclear medicine and molecular imaging, 2014, Volume: 41, Issue:1

    Topics: Aged; Aged, 80 and over; Antigens, Surface; Choline; Gallium Radioisotopes; Glutamate Carboxypeptida

2014
Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.
    European journal of nuclear medicine and molecular imaging, 2014, Volume: 41, Issue:1

    Topics: Aged; Aged, 80 and over; Antigens, Surface; Choline; Gallium Radioisotopes; Glutamate Carboxypeptida

2014
Evaluation of the PET component of simultaneous [(18)F]choline PET/MRI in prostate cancer: comparison with [(18)F]choline PET/CT.
    European journal of nuclear medicine and molecular imaging, 2014, Volume: 41, Issue:1

    Topics: Aged; Aged, 80 and over; Bone Neoplasms; Choline; Humans; Lymphatic Metastasis; Magnetic Resonance I

2014
11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT.
    European journal of nuclear medicine and molecular imaging, 2014, Volume: 41, Issue:5

    Topics: Aged; Aged, 80 and over; Carbon Radioisotopes; Choline; Humans; Male; Middle Aged; Multimodal Imagin

2014
Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014, Volume: 55, Issue:2

    Topics: Aged; Aged, 80 and over; Area Under Curve; Carbon Radioisotopes; Choline; Humans; Image Processing,

2014
Unexpected diagnosis of peripheral schwannoma on 18F-fluoroethylcholine PET/CT for localization of prostate cancer recurrence and biopsy under real-time PET/ultrasound fusion guidance.
    Clinical nuclear medicine, 2014, Volume: 39, Issue:4

    Topics: Aged; Choline; Humans; Image Processing, Computer-Assisted; Image-Guided Biopsy; Incidental Findings

2014
Quantitative evaluation of bone metastases from prostate cancer with simultaneous [18F] choline PET/MRI: combined SUV and ADC analysis.
    Annals of nuclear medicine, 2014, Volume: 28, Issue:5

    Topics: Aged; Aged, 80 and over; Biological Transport; Bone Neoplasms; Carbon Radioisotopes; Choline; Diffus

2014
(11)C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients.
    European journal of nuclear medicine and molecular imaging, 2014, Volume: 41, Issue:7

    Topics: Aged; Aged, 80 and over; Carbon Radioisotopes; Choline; Feasibility Studies; Humans; Lymphatic Metas

2014
Influence of hormonal therapy in prostate cancer patients undergoing [18F]fluoromethyl choline PET/CT: a retrospective study.
    The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2016, Volume: 60, Issue:4

    Topics: Aged; Aged, 80 and over; Biological Transport; Choline; Hormones; Humans; Male; Middle Aged; Positro

2016
(18)F-fluoromethylcholine (FCho), (18)F-fluoroethyltyrosine (FET), and (18)F-fluorodeoxyglucose (FDG) for the discrimination between high-grade glioma and radiation necrosis in rats: a PET study.
    Nuclear medicine and biology, 2015, Volume: 42, Issue:1

    Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Choline; Diagnosis, Differential; Female; Fluorodeoxyglu

2015
(11)C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer.
    Actas urologicas espanolas, 2015, Volume: 39, Issue:4

    Topics: Adenocarcinoma; Bone Neoplasms; Carbon Radioisotopes; Choline; Combined Modality Therapy; Humans; Ly

2015
Optimized protocol for (18)F-choline PET/CT in patients with biochemically relapsed prostate cancer: experiences on 250 consecutive cases.
    Clinical nuclear medicine, 2015, Volume: 40, Issue:6

    Topics: Aged; Choline; Fluorine Radioisotopes; Humans; Male; Middle Aged; Multimodal Imaging; Positron-Emiss

2015
Prognostic value of metabolic parameters and clinical impact of ¹⁸F-fluorocholine PET/CT in biochemical recurrent prostate cancer.
    European journal of nuclear medicine and molecular imaging, 2015, Volume: 42, Issue:12

    Topics: Aged; Aged, 80 and over; Choline; Disease-Free Survival; Follow-Up Studies; Humans; Male; Middle Age

2015
Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with (68)Ga-PSMA-HBED-CC than with (18)F-Fluoroethylcholine PET/CT.
    European journal of nuclear medicine and molecular imaging, 2016, Volume: 43, Issue:8

    Topics: Aged; Choline; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Humans; Lymph Node Excision; Ma

2016
Brain metabolite levels in recently sober individuals with alcohol use disorder: Relation to drinking variables and relapse.
    Psychiatry research. Neuroimaging, 2016, Apr-30, Volume: 250

    Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Aspartic Acid; Brain; Choline; Chronic Dise

2016
Can (68)GA-PSMA or radiolabeled choline PET/CT guide salvage lymph node dissection in recurrent prostate cancer?
    European journal of nuclear medicine and molecular imaging, 2016, Volume: 43, Issue:8

    Topics: Aged; Choline; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Humans; Isotope Labeling; Lymph

2016
18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study.
    European journal of nuclear medicine and molecular imaging, 2016, Volume: 43, Issue:11

    Topics: Aged; Aged, 80 and over; Choline; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Male;

2016
Pituitary Non-Functioning Adenoma Disclosed at 18F-Choline PET/CT to Investigate a Prostate Cancer Relapse.
    Clinical nuclear medicine, 2016, Volume: 41, Issue:10

    Topics: Adenoma; Choline; Humans; Incidental Findings; Male; Middle Aged; Pituitary Neoplasms; Positron Emis

2016
Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence.
    Nuklearmedizin. Nuclear medicine, 2009, Volume: 48, Issue:1

    Topics: Aged; Aged, 80 and over; Choline; Fluorine Radioisotopes; Humans; Male; Middle Aged; Neoplasm Recurr

2009
Hippocampal metabolic abnormalities at first onset and with recurrent episodes of a major depressive disorder: a proton magnetic resonance spectroscopy study.
    NeuroImage, 2009, Aug-01, Volume: 47, Issue:1

    Topics: Adult; Analysis of Variance; Aspartic Acid; Choline; Depressive Disorder, Major; Female; Glutamic Ac

2009
Influence of trigger PSA and PSA kinetics on (11)C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2010, Volume: 51, Issue:3

    Topics: Carbon Radioisotopes; Choline; Humans; Kinetics; Male; Positron-Emission Tomography; Prostate-Specif

2010
Comparison of 18F-FDG and 11C-choline PET/CT for detecting recurrences in patients with nonsquamous cell head and neck malignancies.
    Nuclear medicine communications, 2010, Volume: 31, Issue:11

    Topics: Biological Transport; Carbon Radioisotopes; Choline; Female; Fluorodeoxyglucose F18; Head and Neck N

2010
Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
    European journal of nuclear medicine and molecular imaging, 2011, Volume: 38, Issue:1

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Carbon Radioisotopes; Choline; Early Detection of Can

2011
Utility of ¹¹C-choline imaging as a supplement to F-18 FDG PET imaging for detection of thyroid carcinoma.
    Clinical nuclear medicine, 2011, Volume: 36, Issue:2

    Topics: Adult; Aged; Carbon Radioisotopes; Choline; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Age

2011
Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study.
    European journal of nuclear medicine and molecular imaging, 2011, Volume: 38, Issue:11

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Anilides; Biological Transport; Carbon Rad

2011
Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy.
    European journal of nuclear medicine and molecular imaging, 2012, Volume: 39, Issue:2

    Topics: Aged; Aged, 80 and over; Choline; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Kinetics; Lymph

2012
Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer.
    European journal of nuclear medicine and molecular imaging, 2012, Volume: 39, Issue:6

    Topics: Adult; Aged; Choline; Humans; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; P

2012
Benign fibrous dysplasia on [(11)C]choline PET: a potential mimicker of disease in patients with biochemical recurrence of prostate cancer.
    Annals of nuclear medicine, 2012, Volume: 26, Issue:7

    Topics: Aged; Carbon Radioisotopes; Choline; Diagnosis, Differential; Fibrous Dysplasia of Bone; Humans; Mal

2012
(11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy.
    European journal of nuclear medicine and molecular imaging, 2013, Volume: 40, Issue:2

    Topics: Aged; Aged, 80 and over; Biopsy; Carbon Isotopes; Choline; Hormones; Humans; Image Processing, Compu

2013
Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution.
    Clinical nuclear medicine, 2013, Volume: 38, Issue:1

    Topics: Aged; Aged, 80 and over; Choline; Humans; Male; Middle Aged; Multimodal Imaging; Multivariate Analys

2013
Long-term follow-up of magnetic resonance-detectable choline signal changes in the hippocampus of patients treated with electroconvulsive therapy.
    The Journal of clinical psychiatry, 2003, Volume: 64, Issue:7

    Topics: Aspartic Acid; Choline; Cognition Disorders; Creatine; Depressive Disorder, Major; Electroconvulsive

2003
Reduced NAA levels in the dorsolateral prefrontal cortex of young bipolar patients.
    The American journal of psychiatry, 2005, Volume: 162, Issue:11

    Topics: Adolescent; Adult; Age Factors; Aspartic Acid; Bipolar Disorder; Child; Choline; Creatine; Female; H

2005
[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients.
    European journal of nuclear medicine and molecular imaging, 2006, Volume: 33, Issue:12

    Topics: Aged; Aged, 80 and over; Cell Differentiation; Cell Proliferation; Choline; Humans; Male; Middle Age

2006
The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer.
    European journal of nuclear medicine and molecular imaging, 2008, Volume: 35, Issue:1

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Carbon Radioisotopes; Choline; Humans; Male; Middle A

2008
Response of non-Hodgkin lymphoma to radiation therapy: early and long-term assessment with H-1 MR spectroscopic imaging.
    Radiology, 1995, Volume: 194, Issue:1

    Topics: Aspartic Acid; Brain Neoplasms; Choline; Creatine; Female; Follow-Up Studies; Humans; Lipid Metaboli

1995
[The validation and effect of the prophylactic (antirelapse) treatment of peptic ulcer patients with chlorozil and metronidazole].
    Klinicheskaia meditsina, 1996, Volume: 74, Issue:2

    Topics: Adult; Anti-Ulcer Agents; Choline; Drug Evaluation; Duodenal Ulcer; Female; Follow-Up Studies; Human

1996
Evaluation of multiple sclerosis by 1H spectroscopic imaging at 4.1 T.
    Magnetic resonance in medicine, 1996, Volume: 36, Issue:1

    Topics: Adult; Aspartic Acid; Astrocytes; Axons; Brain; Cell Membrane; Cerebral Ventricles; Choline; Creatin

1996
1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study.
    Journal of neurology, neurosurgery, and psychiatry, 1998, Volume: 64, Issue:2

    Topics: Adult; Brain; Choline; Creatinine; Disability Evaluation; Humans; Inositol; Interferon-beta; Magneti

1998
Magnetic resonance techniques for the identification of patients with symptomatic carotid artery occlusion at high risk of cerebral ischemic events.
    Stroke, 2000, Volume: 31, Issue:12

    Topics: Adult; Aged; Aspartic Acid; Brain Ischemia; Carotid Arteries; Carotid Stenosis; Choline; Comorbidity

2000
Comparative follow-up of enhancement phenomena with MRI and Proton MR Spectroscopic Imaging after intralesional immunotherapy in glioblastoma--Report of two exceptional cases.
    Zentralblatt fur Neurochirurgie, 2002, Volume: 63, Issue:1

    Topics: Adult; Brain Neoplasms; Choline; Fatal Outcome; Female; Glioblastoma; Humans; Image Processing, Comp

2002
[Experience with objective evaluation of the action of cimetidine--a blocker of histamine-H2 receptors--in patients with peptic ulcer of the duodenum].
    Terapevticheskii arkhiv, 1986, Volume: 58, Issue:2

    Topics: Anti-Ulcer Agents; Atropine; Choline; Cimetidine; Duodenal Ulcer; Gastric Acid; Gastric Mucosa; Gast

1986